NASDAQ:VIRX Viracta Therapeutics (VIRX) Stock Price, News & Analysis → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free VIRX Stock Alerts $0.83 -0.02 (-2.36%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.82▼$0.8550-Day Range$0.68▼$1.1752-Week Range$0.43▼$2.38Volume36,928 shsAverage Volume147,309 shsMarket Capitalization$32.53 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Viracta Therapeutics alerts: Email Address Viracta Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside745.1% Upside$7.00 Price TargetShort InterestBearish2.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$2,486 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.10) to ($1.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.29 out of 5 starsMedical Sector733rd out of 916 stocksPharmaceutical Preparations Industry335th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingViracta Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageViracta Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.50% of the float of Viracta Therapeutics has been sold short.Short Interest Ratio / Days to CoverViracta Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Viracta Therapeutics has recently increased by 5.97%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldViracta Therapeutics does not currently pay a dividend.Dividend GrowthViracta Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIRX. Previous Next 0.9 News and Social Media Coverage News SentimentViracta Therapeutics has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Viracta Therapeutics this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 4 people have added Viracta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Viracta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,486.00 in company stock.Percentage Held by InsidersOnly 7.42% of the stock of Viracta Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 31.37% of the stock of Viracta Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Viracta Therapeutics are expected to grow in the coming year, from ($1.10) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viracta Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viracta Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViracta Therapeutics has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Viracta Therapeutics Stock (NASDAQ:VIRX)Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.Read More VIRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIRX Stock News HeadlinesApril 23, 2024 | msn.comDay One wins FDA nod for brain cancer therapy, OjemdaApril 18, 2024 | markets.businessinsider.comPromising Clinical Trial Results Reinforce Buy Rating for Viracta TherapeuticsApril 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.April 18, 2024 | americanbankingnews.comViracta Therapeutics (NASDAQ:VIRX) Given "Outperform" Rating at OppenheimerApril 17, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Viracta Therapeutics (VIRX) and UnitedHealth (UNH)April 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)April 15, 2024 | msn.comWhy Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?April 15, 2024 | globenewswire.comViracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell LymphomaApril 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.April 1, 2024 | globenewswire.comViracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of TaiwanMarch 22, 2024 | investing.comViracta Therapeutics CFO and COO Dan Chevallard resignsMarch 12, 2024 | markets.businessinsider.comBuy Rating for Viracta Therapeutics Backed by Upcoming Catalysts and Solid FinancialsMarch 8, 2024 | msn.comVIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023March 7, 2024 | globenewswire.comViracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 29, 2024 | globenewswire.comViracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 TrialFebruary 17, 2024 | finance.yahoo.comVIRX Mar 2024 2.500 callFebruary 6, 2024 | finance.yahoo.comViracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 4, 2024 | finance.yahoo.comViracta Therapeutics Provides Clinical Update and Outlook for 2024December 22, 2023 | benzinga.comViracta Therapeutics Stock (NASDAQ:VIRX) Dividends: History, Yield and DatesDecember 12, 2023 | msn.comViracta gets orphan drug status for Nana-val for EBV tumorsDecember 12, 2023 | finance.yahoo.comViracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal CarcinomaDecember 4, 2023 | finance.yahoo.comViracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose LevelsNovember 18, 2023 | morningstar.comViracta Therapeutics Inc VIRXNovember 9, 2023 | benzinga.comViracta Therapeutics: Q3 Earnings InsightsNovember 9, 2023 | finance.yahoo.comViracta Therapeutics Inc (VIRX) Reports Q3 2023 Financial Results Amid Clinical AdvancesNovember 9, 2023 | finance.yahoo.comViracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateOctober 5, 2023 | markets.businessinsider.comPromising Developments in Viracta Therapeutics Research and Trials Bolster Buy RatingSee More Headlines Receive VIRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VIRX CUSIPN/A CIK1061027 Webwww.viracta.com Phone(858) 400-8470Fax650-266-3501Employees40Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$13.00 Low Stock Price Target$4.00 Potential Upside/Downside+745.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-172.32% Return on Assets-71.40% Debt Debt-to-Equity RatioN/A Current Ratio1.43 Quick Ratio1.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.33 per share Price / Book2.51Miscellaneous Outstanding Shares39,270,000Free Float36,358,000Market Cap$32.53 million OptionableOptionable Beta0.93 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Mark Andrew Rothera (Age 61)CEO, President & Director Comp: $365.03kDr. Susan Perrine M.D.Scientific Founder and ConsultantDr. Ronald J. Berenson M.D. (Age 72)Co-Founder and Consultant Mr. George HillmanCo-FounderDr. Thalia Papayannopoulou M.D.Co-FounderDr. Robert M. Williams Ph.D. (Age 69)Co-Founder Dr. Douglas V. Faller M.D.Ph.D., Scientific Founder & Chairman of Scientific Advisory BoardMs. Melody Burcar CPA (Age 41)M.B.A., Senior VP of Finance, Interim Principal Financial Officer & Interim Principal Accounting Officer Dr. Ayman El-GuindyChief Scientific OfficerMr. Stewart M. BrownSenior VP of Legal Affairs & General CounselMore ExecutivesKey CompetitorsVYNE TherapeuticsNASDAQ:VYNECASI PharmaceuticalsNASDAQ:CASITheratechnologiesNASDAQ:THTXAcurx PharmaceuticalsNASDAQ:ACXPImmunoPrecise AntibodiesNASDAQ:IPAView All CompetitorsInsidersDaniel R ChevallardSold 3,405 sharesTotal: $2,485.65 ($0.73/share)Mark RotheraBought 52,094 shares on 11/30/2023Total: $25,526.06 ($0.49/share)Daniel R ChevallardSold 3,720 sharesTotal: $1,860.00 ($0.50/share)Daniel R ChevallardSold 3,512 sharesTotal: $5,092.40 ($1.45/share)Daniel R ChevallardSold 3,635 sharesTotal: $5,161.70 ($1.42/share)View All Insider Transactions VIRX Stock Analysis - Frequently Asked Questions Should I buy or sell Viracta Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viracta Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VIRX shares. View VIRX analyst ratings or view top-rated stocks. What is Viracta Therapeutics' stock price target for 2024? 4 Wall Street research analysts have issued 12 month price objectives for Viracta Therapeutics' shares. Their VIRX share price targets range from $4.00 to $13.00. On average, they predict the company's share price to reach $7.00 in the next year. This suggests a possible upside of 745.1% from the stock's current price. View analysts price targets for VIRX or view top-rated stocks among Wall Street analysts. How have VIRX shares performed in 2024? Viracta Therapeutics' stock was trading at $0.57 at the beginning of 2024. Since then, VIRX stock has increased by 45.3% and is now trading at $0.8283. View the best growth stocks for 2024 here. When is Viracta Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our VIRX earnings forecast. How were Viracta Therapeutics' earnings last quarter? Viracta Therapeutics, Inc. (NASDAQ:VIRX) issued its earnings results on Thursday, March, 7th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.05. How do I buy shares of Viracta Therapeutics? Shares of VIRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIRX) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
